Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
Not yet recruitingOBSERVATIONAL
Enrollment
820
Participants
Timeline
Start Date
September 30, 2025
Primary Completion Date
September 30, 2030
Study Completion Date
January 31, 2032
Conditions
Resectable Pancreatic Duct Adenocarcinoma
Trial Locations (1)
76031
CHU de Rouen, Rouen
All Listed Sponsors
collaborator
Federation of Research in Surgery (FRENCH)
OTHER
lead
University Hospital, Rouen
OTHER
NCT07034703 - Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial | Biotech Hunter | Biotech Hunter